1 completed, 1 recruiting, 1 terminated. 2 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Recruiting 1, Terminated 1 |
| Phase 1 | 1 | Completed 1 |
Follow ASP3662: new trials by email Literature Review of ASP3662 trials Research Report on ASP3662
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Trial Against INtractable Type 2 Diabetes (CAPTAIN-T2D) clofutriben, Placebo - Type 2 Diabetes, Cortisol Excess | Phase 2 | Recruiting | Sparrow Pharmaceuticals | 1500 | 2025-11-29 | 2026-10-06 |
| Study to Assess Analgesic Efficacy and Safety of ASP3662 in Subjects With Painful Diabetic Peripheral Neuropathy ASP3662, pregabalin, ASP3662 placebo - Painful Diabetic Peripheral Neuropathy (PDPN) | Phase 2 | Terminated | Astellas Pharma Global Development, Inc. | 115 | 2015-05-27 | 2019-03-26 |
| A Positron Emission Tomography Occupancy Study Using Ligand [11C]AS2471907 and Following Oral Dosing of ASP3662 [11C]AS2471907, Positron Emission Tomography (PET), ASP3662 - Pharmacokinetics of ASP3662, Displacement of Radiotracer | Phase 1 | Completed | Astellas Pharma Global Development, Inc. | 18 | 2014-04-01 | 2016-06-28 |
ACTH Syndrome, Ectopic (1) · Cushing Syndrome (1) · Diabetes Mellitus, Type 2 (1)
Astellas Pharma Global Development, Inc. (2) · Sparrow Pharmaceuticals (1)
United States (3)